This study investigated the relationship between lymphocyte (a type of white blood cells) counts and treatment outcomes for patients with rectal cancer. Researchers suggested that lymphocyte count reduction may be caused by rectal cancer treatment and is associated with better tumor response.

This phase 3 trial is examining the effectiveness of a combination treatment with panitumumab (Vectibix), leucovorin and fluorouracil after chemotherapy combined with panitumumab in metastatic (spread to other parts of the body) colorectal cancer.

The main outcome to be measured is progression-free survival (PFS; time from treatment to cancer growing or spreading) and tumor response. This study is being conducted in the US, in California.

This article investigated the short- and long-term outcomes of patients with rectal cancer who underwent robotic-assisted laparoscopic surgery (RALS).

The authors concluded that RALS is beneficial and has good short- and long-term outcomes. 

This study investigated the impact of the thyroid hormones (TH) on survival outcomes of patients with colorectal cancer treated with regorafenib (Stivarga). Researchers suggested that TH ratio can predict the outcomes in these patients.

This study investigated the effectiveness of panitumumab (Vectibix) and the predictive factors for the treatment of metastatic (spread to other parts of the body) colorectal cancer. Researchers suggested that this treatment was effective for these patients and that early tumor shrinkage and RAS mutation (permanent change) are good predictive factors of the outcomes of the treatment.

This study investigated the effectiveness and safety of regorafenib (Stivarga) to treat patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC) that progressed after initial treatment. Researchers suggested that regorafenib is a safe option to treat these patients.

This review analyzed a number of studies evaluating the risk factors for anastomotic leakage in patients undergoing colorectal cancer resection.

This study investigated whether circulating DNA can be useful for predicting the outcome of patients treated with irinotecan (Campto). 

This study developed a new method for assessing Crohn’s-like lymphoid reaction (CLR) in patients with colorectal cancer. It also examined if CLR can be useful for predicting patient outcome.

This study evaluated the impact of delayed chemotherapy on long-term outcomes in rectal cancer patients.